

## COVID-19 Press Briefing

May 7, 2021







#### The Vaccination Progress Report

**57%** of adult Americans now have at least one shot.

The President's Goal: 70% of adult Americans with at least one shot by July 4th.



#### Daily Change in COVID-19 Cases, US

January 22, 2020 - May 5, 2021

TOTAL Cases Reported Since 1/22/20

32,356,034

NEW Cases Reported to CDC on 5/5/21

41,909

Change in 7-Day Case Average


-13.2%

Current 7-Day Case Average (4/29/21 - 5/5/21)

45,817

Prior 7-Day Case Average (4/22/21 - 4/28/21)

52,772







#### New Admissions of Patients with Confirmed COVID-19

August 1, 2020 – May 4, 2021

Patients Currently Hospitalized with COVID on 5/4/21

32,391

New Admissions on 5/4/21

4,710

Peak in New Admissions (1/5/21)

17,942

Change in 7-Day Average of New Admissions


-8.4%

Current 7-Day Average of New Admissions (4/28/21 - 5/4/21)

4,640

Prior 7-Day Average of New Admissions (4/21/21 - 4/27/21)

5,066







#### Daily Change in COVID-19 Deaths, United States

January 22, 2020 – May 5, 2021

TOTAL Deaths Reported Since 1/22/2020

576,238

NEW Deaths Reported to CDC on 5/5/21 730

Change in 7-Day Death Average

+3.8%

Current 7-Day Death Average (4/29/21 - 5/5/21)


656

Prior 7-Day Death Average (4/22/21 - 4/28/21)

632

Forecasted Total Deaths by 5/29/21

586,000 to 600,000







# Striking Effectiveness of COVID-19 Vaccines: Potential Impact on the Global Pandemic





## THE LANCET

published online May 5, 2021


Impact and Effectiveness of mRNA BNT162b2 Vaccine Against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths Following a Nationwide Vaccination Campaign in Israel: An Observational Study Using National Surveillance Data

EJ Haas, S Alroy-Preis et al.






#### **Daily Laboratory-Confirmed SARS-CoV-2 Infections in Israel –** Nov. 1, 2020 to April 3, 2021





#### Effect of Robust COVID-19 Vaccination Program in Israel







# Estimated Effectiveness of 2 Doses of Pfizer/BioNTech COVID-19 Vaccine Against 6 Outcomes, Israel

- All ages, 201.9 million person-years total
- B.1.1.7 variant accounted for ~95% of SARS-CoV-2 infections

### Estimated adjusted effectiveness, ≥7 days after the second dose, Jan 24 to April 3, 2021

	,
SARS-CoV-2 infection	95.3%
Asymptomatic SARS-CoV-2 infection	91.5
Symptomatic COVID-19	97.0
COVID-19-related hospitalization	97.2
Severe or critical COVID-19-related hospitalization	97.5
COVID-19-related death	96.7

Source: EJ Haas et al. Lancet, 5/5/2021.



# Estimated Effectiveness of 2 Doses of Pfizer/BioNTech COVID-19 Vaccine Against SARS-CoV-2 Infection, by Age Group, Israel

Estimated adjusted effectiveness, ≥7 days after the second dose, Jan 24 to April 3, 2021

Age Group	VE vs. SARS-CoV-2 infection
All ages	95.3%
Age 16-44 years	96.1
Age 45-64 years	94.9
Age ≥65 years	94.8
Age ≥75 years	95.1
Age ≥85 years	94.1

Source: EJ Haas et al. Lancet, 5/5/2021.



#### Implications of Lancet Report from Israel

"These findings are of international importance as vaccination programs ramp up across the rest of the world, suggesting that other countries can similarly achieve marked and sustained declines in SARS-CoV-2 incidence if they can achieve high vaccine uptake."







## Effectiveness of the BNT162b2 COVID-19 Vaccine against the B.1.1.7 and B.1.351 Variants

LJ Abu-Raddad et al. for the National Study Group for COVID-19 Vaccination

- Mass vaccination campaign in Qatar; total n=385,853
- Vaccine effectiveness against any documented infection
  - **B.1.1.7** -- 89.5% after 2 doses, 29.5% after 1 dose
  - B.1.351 -- 75.0% after 2 doses, 16.9% after 1 dose
- Vaccine effectiveness against severe, critical, or fatal disease
  - **B.1.1.7** -- 100% after 2 doses, 54.1% after 1 dose
  - B.1.351 -- 100% after 2 doses, 0% after 1 dose





# 70% of adults vaccinated with at least 1 dose by July 4







THE WHITE HOUSE WASHINGTON

#### WH.GOV